Sentences with phrase «year by the drugs»

Not exact matches

Besides Oakland residents arrested within the city for pot crimes dating back to 1996, the permits are available to residents living at least 10 of the past 20 years in police beats torn apart by the war on drugs.

By contrast, while the cost of older, branded pharmaceuticals continue to rise and contribute to increased spending, when discounting is considered, prices of these drugs increased, on average, 2.8 % in 2015, the lowest growth rate in years.

Stevia was approved by the Food and Drug Administration nearly six years ago, and since it comes from the leaves of a plant and has no calories, it has led the charge in the search for more natural alternatives to sugar.

But sales of Praluent and a rival Amgen drug, with list prices of more than $ 14,000 a year before discounts, have been severely constrained by onerous roadblocks to patient access by insurers.

But sales of Praluent and a rival Amgen drug, with list prices of more than $ 14,000 a year before discounts, have been constrained by onerous roadblocks to patient access by insurers.

The facility where the investigators had assembled that morning, brandishing an Administrative Inspection Warrant, was a distribution center operated by one of America's largest public companies, the giant drug wholesaler McKesson (mck), which ranks No. 5 on this year's Fortune 500.

Shares of pioneering CRISPR gene - editing firm Editas fell 7 % in early Tuesday trading after the company announced that it would delay an initial FDA filing for clinical trials of one of its lead drugs, LCA10, to the middle of next year (Editas had originally planned to file by the end of 2017).

For years QHR Technologies (recently acquired by Loblaw Cos.» Shoppers Drug Mart) and Telus Health (a division of the telecom) fought tooth and nail to get health authorities to digitize patients» medical records using their respective systems.

Last year, he was suspended for six months by the PGA Tour after a positive drug test.

After fighting unsuccessfully to reverse generic drug laws last year, and the sudden resignation of its CEO, Shoppers Drug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher Interbrdrug laws last year, and the sudden resignation of its CEO, Shoppers Drug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher InterbrDrug Mart has suffered a 17 % drop in «brand value,» to $ 2.6 billion, according to a study conducted by researcher Interbrand.

The Pittsburgh - based specialty pharmacy grew its revenue by 13,380 percent in three years to $ 42 million by focusing on the small populations of underserved patients who need orphan drugs to treat serious illnesses.

Walmsley, who took over a year ago, is focusing on rebuilding GSK's drug pipeline by overhauling research and appointing heavyweight outsiders, such as veteran Roche scientist Hal Barron.

As lawmakers and the public scrutinize dramatic price increases for other old drugs — most recently with the Mylan - owned EpiPen, which saw its cost go up by 500 % in the past nine years — the next flash point may be insulin, a drug both ubiquitous and complicated.

And for 27 years, before he was elected sheriff, he presided over court cases — ones that increasingly involved the stories of lives undone by drugs and poverty, and of an opioid epidemic taking root.

Despite this threat, and looming competition from a new Gilead Sciences HIV drug, GSK sees growth strengthening over the next few years, helped by the roll - out of newer medicines.

If you haven't followed this story, you'll remember Shkreli from his fame two years ago, when his biotech firm, Turing Pharmaceuticals, acquired the patent to a drug used to treat malaria, cancer and aids, and jacked up the retail price by more than 5,000 percent.

That's why the 21st Century Cures Act, which aims to streamline the drug approval process, was overwhelmingly approved by Congress last year and signed into law by President Barack Obama.

And after announcing a «social contract» to keep drug price hikes below 10 percent a year, his company raised a slew of prices by 9.5 percent.

KFC, China's biggest restaurant chain with more than 4,000 outlets and plans to open 700 more this year, was hit hard by a report in December 2013 that some poultry suppliers violated rules on drug use in chickens.

According to a study published last year by the National Bureau of Economic Research, American consumers are spending an estimated extra $ 44 billion a year on brand - name drugs, health care items and pantry goods.

At 16 years old, I was a full - blown drug addict who was completely throwing his entire life away by living a life with no meaning and surrounding myself with others who degraded my potential and ability to become the best version of myself.

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

Though hailed as «a new therapeutic principle» in 1990, it nonetheless took another eight years for the FDA to approve the first antisense drug, fomivirsen — for the treatment of AIDS - related retinitis caused by human cytomegalovirus.

The 32 - year - old CEO of Turing Pharmaceuticals became a target of widespread ire in September when he boosted the price of the toxoplasmosis treatment Daraprim by over 5,000 % after acquiring the drug in August.

India - based drug manufacturing facilities have been criticized by the FDA in recent years for violating quality standards, as the agency increases oversight of key suppliers to the United States.

2018 will be a defining year for Mexico, a country plagued by corruption, violence in its struggle against gangs and drug cartels, and slow economic growth.

There is at least some good news: The FDA in May approved Radicava, the first ALS drug greenlighted in 22 years on an application by the Mitsubishi Tanabe Pharma Corporation, a subsidiary of the tech giant.

U.S. drugmaker Turing Pharmaceuticals, led at the time by hedge fund manager Martin Shkreli, caused outrage last year by raising the U.S. price of Daraprim, an old anti-infective drug, by more than 5,000 % to $ 750 a pill.

After all, inflation (and even medical inflation, which tends to be higher than regular inflation) is well below 9.9 %, meaning a year - to - year 7 % or 8 % increase on major drugs isn't necessarily justified by market dynamics.

A Wall Street Journal investigation earlier this year linked companies controlled by Canada Drugs through its wholesale division to a shipment of a fake cancer drug, though the FDA hasn't reached a conclusion.

Studies have found that longer sentences do not have appreciably greater deterrent effects; many serious crimes are committed by people under the influence of alcohol or drugs, who are not necessarily thinking of the consequences of their actions, and certainly are not affected by the difference between a 15 - year and a 30 - year sentence.

Although most retailers are quick to say they're unfazed by the entrance of the U.S. retail giant, some, including Shoppers Drug Mart (TSX: SC), Hudson's Bay Co. (TSX: HBC), Canadian Tire (TSX: CTC.A) and Loblaw (TSX: L), have scrambled in the past year to become more competitive.

Though it's not a perfect treatment, Eli Lilly's solanezumab — a drug 15 years in the making — will pass muster in clinical tests and be well on its way to FDA approval, as a therapy for mild Alzheimer's, by year's end.

The drug is called Acthar, and for the past year it has been the focus of a study by the Oregon Health and Science University School of Medicine and Oregon State that has been trying to understand why doctors keep prescribing it for ailments it has never been proved to treat effectively.

After all, as Regeneron CEO Len Schleifer pointed out, pricing a drug to its value would suggest that its price shouldn't have to be raised year after year, even if it's by the single digits.

In Ohio, figures from 88 county coroners show that more than 4,100 people died from drug overdoses last year, according to figures compiled recently by the Columbus Dispatch.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The expiration date, typically just one or two years after manufacture, simply shows how long the maker tested the drug's stability by exposing it to extreme temperatures, humidity and light.

Further, I showed that Pharma's IRR has followed a rapid and steady linear decline over 20 years, which is consistent with recent estimates from BCG and Deloitte, and can be fully explained by the Law of Diminishing Returns as a natural and unavoidable consequence of prioritizing a limited set of investment opportunities while each new drug raises the bar for the next.

Prices for the top 20 drugs prescribed to seniors rose by an average of 12 percent every year from 2012 to 2017.

Each drug is listed by name, sponsor (s), diseases indicated, 2014 sales, 2013 sales, and the percentage change between both years.

After years of buying up companies then raising the prices of their drugs — a strategy that rapidly amplified Valeant's revenue and stock price — Valeant is now struggling to grow by other means, while dealing with the consequences of its previous actions.

Pharmaceutical giant Mylan was embroiled in a controversy about its drug pricing last year when it hiked the price of EpiPen by more than 400 percent.

Valeant became the face of high American drug prices when it acquired Isuprel and Nitropress last year and immediately raised their prices by 525 percent and 212 percent.

Papa said discounts for the two drugs may rise as the program is expanded, and cheaper competing versions of the drugs will come to market by the end of next year.

The campaign also said that Prop 61 «would invalidate many drug discount agreements the state has negotiated with pharmaceutical companies,» which would increase state prescription costs by tens of millions of dollars each year.

Last year, the U.S. Food and Drug Administration agreed to «fast - track» its Niraparib review process, raising the likelihood it could hit the market by 2018.

(Reuters)- AbbVie Inc (ABBV.N) forecast its flagship drug Humira to bring $ 21 billion in sales by 2020, about $ 3 billion higher than its expectation two years ago, driving the U.S. drugmaker's shares up 4 percent on Friday.

But the company was hit by regulatory and political scrutiny in the past year over its drug pricing and its relationship to a mail - order pharmacy, and its stock took a beating.

But the lack of public disclosure by Health Canada raises new questions about what controls are in place to ensure the product is free of contaminants and chemicals, particularly as the government prepares to introduce legislation to legalize the drug next year.